Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial

被引：2

作者：

Eggermont, A. M. M. ^{[1
]}

Chiarion-Sileni, V. ^{[2
]}

Grob, J-J. ^{[3
]}

Dummer, R. ^{[4
]}

Wolchok, J. D. ^{[5
]}

Schmidt, H. ^{[6
]}

Hamid, O. ^{[7
]}

Robert, C. ^{[8
]}

Ascierto, P. A. ^{[9
]}

Richards, J. M. ^{[10
]}

Lebbe, C. ^{[11
,12
]}

Ferraresi, V. ^{[13
]}

Smylie, M. ^{[14
]}

Weber, J. S. ^{[15
]}

Taitt, C. ^{[16
]}

de Pril, V. ^{[17
]}

de Schaetzen, G. ^{[18
,19
]}

Suciu, S. ^{[18
,19
]}

Testori, A. ^{[20
]}

机构：

[1] Gustave Roussy Canc Campus Grand Paris, Oncol Surg, Villejuif, France

[2] IRCCS, IOV, Dept Dermatol, Melanoma Oncol Unit, Padua, Italy

[3] Aix Marseille Univ, Hop La Timone APHM, Dept Dermatol & Skin Canc, Marseille, France

[4] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland

[5] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, 1275 York Ave, New York, NY 10021 USA

[6] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark

[7] Angeles Clin & Res Inst, Clin Res, Los Angeles, CA USA

[8] Gustave Roussy Canc Campus Grand Paris, Dermatol Unit, Villejuif, France

[9] Fdn G Pascale, Ist Nazl Tumori, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy

[10] Oncol Specialists SC, Div Hematol Oncol, Park Ridge, IL USA

[11] Univ Paris 07, INSERM, U976, Hop St Louis,APHP,Dept Dermatol, Paris, France

[12] Univ Paris 07, INSERM, U976, Hop St Louis,APHP,CIC Dept, Paris, France

[13] Ist Fisioterapici Ospitalieri, Dept Med Oncol, Rome, Italy

[14] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada

[15] H Lee Moffitt Canc Ctr & Res Inst, Dept Med, Tampa, FL USA

[16] Bristol Myers Squibb, Worldwide Med, Princeton, NJ USA

[17] Bristol Myers Squibb, Worldwide Med, Braine Lalleud, Belgium

[18] EORTC Headquarters, Melanoma Grp, Brussels, Belgium

[19] EORTC Headquarters, Melanoma Grp, Brussels, Belgium

[20] European Inst Oncol, Div Melanoma & Sarcomi Muscolocutanei, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw435.35

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA2_PR

引用

页数：1

共 50 条

[1] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Eggermont, Alexander M. M.
Chiarion-Sileni, Vanna
Grob, Jean-Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo A.
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Konto, Cyril
Hoos, Axel
de Pril, Veerle
Gurunath, Ravichandra Karra
de Schaetzen, Gaetan
Suciu, Stefan
Testori, Alessandro
LANCET ONCOLOGY, 2015, 16 (05): : 522 - 530
[2] IPILIMUMAB VERSUS PLACEBO AFTER COMPLETE RESECTION OF STAGE III MELANOMA: EFFICACY AND SAFETY RESULTS FROM THE EORTC 18071 PHASE III TRIAL
Eggermont, Alexander M.
Chiarion-Sileni, Vanna
Grob, Jean J.
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo A.
Richards, Jon M.
Ferraresi, Virginia
Smylie, Michael
Weber, Jeff S.
Maio, Michele
Konto, Cyril
de Pril, Veerle
Suciu, Stefan
Testori, Alessandro
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 175 - 175
[3] Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.
Eggermont, Alexander M. M.
Chiarion-Sileni, Vanna
Grob, Jean Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo Antonio
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Hosein, Fareeda
de Pril, Veerle
Kicinski, Michal
Suciu, Stefan
Testori, Alessandro
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[4] Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safely results from the EORTC 18071 phase III trial
Eggerrnont, Alexander M.
Chiarion-Sileni, Vanna
Grob, Jean Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo Antonio
Richards, Jon M.
Lobbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Konto, Cyril
Gurunath, Ravichandra Karra
de Pril, Veerle
Suciu, Stefan
Testorl, Alessandro
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[5] Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.
Eggermont, Alexander M.
Chiarion-Sileni, Vanna
Grob, Jean Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo Antonio
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Konto, Cyril
Gurunath, Ravichandra Karra
de Pril, Veerle
Suciu, Stefan
Testori, Alessandro
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
[6] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial (vol 16, pg 522, 2015)
Eggermont, A. M. M.
Chiarion-Sileni, V
Grob, J-J
LANCET ONCOLOGY, 2015, 16 (06): : E262 - E262
[7] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (vol 16, pg 522, 2015)
Eggermont, A. M. M.
Chiarion-Sileni, V
Grob, J-J
LANCET ONCOLOGY, 2016, 17 (06): : E223 - E223
[8] Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
Weber, J.
Mandala, M.
Del Vecchio, M.
Gogas, H.
Arance, A. M.
Cowey, L. C.
Dalle, S.
Schenker, M.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Grob, J-J.
Butler, M.
Middleton, M. R.
Maio, M.
Atkinson, V.
Queirolo, P.
de Pril, V.
Qureshi, A.
Larkin, J.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2017, 28
[9] Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
Coens, Corneel
Suciu, Stefan
Chiarion-Sileni, Vanna
Grob, Jean-Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo A.
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Bottomley, Andrew
Kotapati, Srividya
de Pril, Veerle
Testori, Alessandro
Eggermont, Alexander M. M.
LANCET ONCOLOGY, 2017, 18 (03): : 393 - 403
[10] Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Eggermont, Alexander M. M.
Chiarion-Sileni, Vanna
Grob, Jean-Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo Antonio
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Hosein, Fareeda
de Pril, Veerle
Kicinski, Michal
Suciu, Stefan
Testori, Alessandro
EUROPEAN JOURNAL OF CANCER, 2019, 119 : 1 - 10

← 1 2 3 4 5 →